KPV

KPV is a tripeptide (Lys-Pro-Val) corresponding to the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (a-MSH), the full 13-amino acid melanocortin peptide. KPV retains the anti-inflammatory signalling activity of a-MSH but does not activate the melanocortin receptors (MC1R-MC5R) responsible for a-MSH's pigmentation effects — this is because the receptor-binding domain of a-MSH resides in its N-terminal and core regions, not the C-terminal KPV sequence. KPV's anti-inflammatory mechanism operates through modulation of inflammatory signalling pathways: it inhibits the nuclear factor-kB (NF-kB) pathway, reducing the transcription of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. KPV also modulates the MAPK signalling cascade and suppresses the activation of inflammatory cells (macrophages, neutrophils), reducing the release of reactive oxygen species and proteolytic enzymes at inflammation sites. In intestinal mucosal inflammation research, KPV has been studied for its effects on colonic epithelial function, where it modulates the inflammatory environment that characterises inflammatory bowel disease models. The tripeptide's separation of anti-inflammatory activity from melanocortin receptor agonism makes it a valuable research tool for studying inflammation modulation without the pigmentation, cardiovascular, or metabolic effects of full-length melanocortin agonists.